Discussion
==========

Oncomine \[[@B1]\] meta-analysis was performed as previously described \[[@B2],[@B3]\]. Briefly, 15 multi-array studies were analyzed for common overlapping co-expressed genes of SUMO1, using muti-array studies within the Oncomine integrated cancer database. This technique gives insight into which pathways the searched gene (in this case *SUMO1*) are involved in, although it is impossible to tell if co-expressed gene products are complexed to SUMO1, act upstream of SUMO1 or downstream of SUMO1. Therefore, while limited, this technique is important for generating leads to assess both the pathways SUMO1 is important for, and regulation of SUMO1 itself.

After meta-analysis there were over 400 consistently co-expressed genes at the cutoff of 3 studies (Additional File [1](#S1){ref-type="supplementary-material"}). Table [1](#T1){ref-type="table"} shows the genes with the higher cutoff of 4 studies. This high number may be expected as SUMO1 is a general factor and involved in many processes. I note that the archetype SUMO1-modified promyelocytic leukemia (PML) was co-expressed with SUMO1, acting as validation of the results \[[@B4]\]. While the Ubc9 conjugation enzyme was not found to be co-expressed many other ubiquitin-conjugating enzymes were (*UBE2N*, *UBE4A*, *UBE2G1*, *UBE2V2*, *UBE2E1*, *UBE2D2*, *UBE2A*, *UBE1C*, *CUL4A*), as was the SUMO1 activating enzyme subunit 2 (*UBA2*). Transcription factors shown to be modified by SUMO were also co-expressed, such as HIF1α, Rb, YY1, and SMAD4 \[[@B5]-[@B9]\]. Interestingly RARα is also co-expressed and while it has never been shown to be a target of SUMO1 the PML-RARα fusion has been shown to be a target of SUMO1 mediated degradation \[[@B10]\]. It would be interesting to investigate if RARα itself is a SUMO1 target. Also co-expressed is the NF-κB subunit RelA. While RelA also is not a proven target of SUMO1 NF-κB is regulated indirectly by SUMO1 modification of Iκ Kgamma/NEMO or IκB \[[@B11],[@B12]\].

###### 

Oncomine meta-analysis of SUMO1 co-expressed genes

  **GENE**   **%**   **GENE NAME**
  ---------- ------- ---------------------------------------------------------------------------------------------
  SUMO1      100%    SMT3 suppressor of mif two 3 homolog 1 (S. cerevisiae)
  DAD1       67%     defender against cell death 1
  DEK        53%     DEK oncogene (DNA binding)
  UBE2N      47%     ubiquitin-conjugating enzyme E2N (UBC13 homolog, yeast)
  SET        47%     SET translocation (myeloid leukemia-associated)
  SLC25A5    40%     solute carrier family 25 (mitochondrial carrier; adenine nucleotide translocator), member 5
  SFRS3      40%     splicing factor, arginine/serine-rich 3
  RPA1       40%     replication protein A1, 70 kDa
  RCN2       40%     Reticulocalbin 2, EF-hand calcium binding domain
  RB1        40%     retinoblastoma 1 (including osteosarcoma)
  PSMD14     40%     proteasome (prosome, macropain) 26S subunit, non-ATPase, 14
  PSMC2      40%     proteasome (prosome, macropain) 26S subunit, ATPase, 2
  PSMA2      40%     proteasome (prosome, macropain) subunit, alpha type, 2
  NUP153     40%     nucleoporin 153 kDa
  GLO1       40%     glyoxalase I
  DPM1       40%     dolichyl-phosphate mannosyltransferase polypeptide 1, catalytic subunit
  DARS       40%     Aspartyl-tRNA synthetase
  CD164      40%     CD164 antigen, sialomucin
  CCT8       40%     chaperonin containing TCP1, subunit 8 (theta)
  BNIP2      40%     BCL2/adenovirus E1B 19 kDa interacting protein 2
  YY1        33%     YY1 transcription factor
  VPS16      33%     vacuolar protein sorting 16 (yeast)
  USP1       33%     ubiquitin specific protease 1
  UBE4A      33%     ubiquitination factor E4A (homologous to yeast UFD2)
  UBE2G1     33%     ubiquitin-conjugating enzyme E2G 1 (UBC7 homolog, C. elegans)
  TSNAX      33%     translin-associated factor X
  SSBP1      33%     single-stranded DNA-binding protein 1
  SMAD4      33%     SMAD, mothers against DPP homolog 4 (Drosophila)
  SIAHBP1    33%     siah binding protein 1
  SEC61B     33%     Sec61 beta subunit
  RIF1       33%     RAP1 interacting factor homolog (yeast)
  RBMX       33%     RNA binding motif protein, X-linked
  PSMA3      33%     proteasome (prosome, macropain) subunit, alpha type, 3
  PPP6C      33%     protein phosphatase 6, catalytic subunit
  POLD2      33%     polymerase (DNA directed), delta 2, regulatory subunit 50 kDa
  NCBP2      33%     nuclear cap binding protein subunit 2, 20 kDa
  IRS1       33%     insulin receptor substrate 1
  ILF3       33%     interleukin enhancer binding factor 3, 90 kDa
  HMGN4      33%     high mobility group nucleosomal binding domain 4
  H2AFV      33%     H2A histone family, member V
  G22P1      33%     thyroid autoantigen 70 kDa (Ku antigen)
  EIF2S3     33%     eukaryotic translation initiation factor 2, subunit 3 gamma, 52 kDa
  CUL1       33%     cullin 1
  C10orf7    33%     chromosome 10 open reading frame 7
  BZW1       33%     basic leucine zipper and W2 domains 1
  BRD2       33%     bromodomain-containing 2
  ATP6V0B    33%     ATPase, H+ transporting, lysosomal 21 kDa, V0 subunit c\'
  ATP5J      33%     ATP synthase, H+ transporting, mitochondrial F0 complex, subunit F6
  WEE1       27%     WEE1 homolog (S. pombe)
  VBP1       27%     von Hippel-Lindau binding protein 1 (prefoldin 3)
  UQCRC1     27%     ubiquinol-cytochrome c reductase core protein I
  UBXD2      27%     UBX domain containing 2
  TSN        27%     translin
  TNIP1      27%     TNFAIP3 interacting protein 1
  TEBP       27%     unactive progesterone receptor, 23 kD
  TAX1BP3    27%     Tax1 (human T-cell leukemia virus type I) binding protein 3
  TANK       27%     TRAF family member-associated NFKB activator
  SYPL       27%     synaptophysin-like protein
  SUPT6H     27%     suppressor of Ty 6 homolog (S. cerevisiae)
  SUPT5H     27%     suppressor of Ty 5 homolog (S. cerevisiae)
  SUCLG1     27%     succinate-CoA ligase, GDP-forming, alpha subunit
  SRI        27%     sorcin
  SON        27%     SON DNA binding protein
  SNRPD3     27%     small nuclear ribonucleoprotein D3 polypeptide 18 kDa
  SNAP23     27%     synaptosomal-associated protein, 23 kDa
  SMAP       27%     small acidic protein
  S100A11    27%     S100 calcium binding protein A11 (calgizzarin)
  RW1        27%     RW1 protei
  RSN        27%     restin (Reed-Steinberg cell-expressed intermediate filament-associated protein)
  RPL36AL    27%     ribosomal protein L36a-like
  RPA3       27%     replication protein A3, 14 kDa
  RNF4       27%     ring finger protein 4
  RBL2       27%     retinoblastoma-like 2 (p130)
  RBBP4      27%     retinoblastoma binding protein 4
  RARS       27%     arginyl-tRNA synthetase
  RANBP2     27%     RAN binding protein 2
  RAE1       27%     RAE1 RNA export 1 homolog (S. pombe)
  RAB1A      27%     RAB1A, member RAS oncogene family
  PXMP3      27%     peroxisomal membrane protein 3, 35 kDa (Zellweger syndrome)
  PTPN12     27%     protein tyrosine phosphatase, non-receptor type 12
  PTMA       27%     prothymosin, alpha (gene sequence 28)
  PSMA5      27%     proteasome (prosome, macropain) subunit, alpha type, 5
  PSMA4      27%     proteasome (prosome, macropain) subunit, alpha type, 4
  PRKDC      27%     protein kinase, DNA-activated, catalytic polypeptide
  PML        27%     promyelocytic leukemia
  PHKB       27%     phosphorylase kinase, beta
  NOLC1      27%     nucleolar and coiled-body phosphoprotein
  MUC2       27%     mucin 2, intestinal/tracheal
  MPI        27%     mannose phosphate isomerase
  MGAT1      27%     mannosyl (alpha-1,3-)-glycoprotein beta-1,2-N-acetylglucosaminyltransferase
  MCP        27%     membrane cofactor protein (CD46, trophoblast-lymphocyte cross-reactive antigen)
  MARK3      27%     MAP/microtubule affinity-regulating kinase 3
  MARK2      27%     MAP/microtubule affinity-regulating kinase 2
  MARCKS     27%     myristoylated alanine-rich protein kinase C substrate
  MAP2K3     27%     mitogen-activated protein kinase kinase 3
  LIMK2      27%     LIM domain kinase 2
  LEREPO4    27%     likely ortholog of mouse immediate early response, erythropoietin 4
  KPNA2      27%     karyopherin alpha 2 (RAG cohort 1, importin alpha 1)
  KIAA0092   27%     translokin
  IL13RA1    27%     interleukin 13 receptor, alpha 1
  HSPE1      27%     heat shock 10 kDa protein 1 (chaperonin 10)
  HNRPA0     27%     heterogeneous nuclear ribonucleoprotein A0
  HMGN3      27%     high mobility group nucleosomal binding domain 3
  HLA-A      27%     major histocompatibility complex, class I, A
  HIF1A      27%     hypoxia-inducible factor 1, alpha subunit (basic helix-loop-helix transcription factor)
  HAT1       27%     histone acetyltransferase 1
  HADHA      27%     hydroxyacyl-Coenzyme A dehydrogenase/3-ketoacyl-Coenzyme A
                     thiolase/enoyl-Coenzyme A hydratase (trifunctional protein), alpha subunit
  GTF3C2     27%     general transcription factor IIIC, polypeptide 2, beta 110 kDa
  GRSF1      27%     G-rich RNA sequence binding factor 1
  GA17       27%     dendritic cell protein
  G3BP       27%     Ras-GTPase-activating protein SH3-domain-binding protein
  FUBP3      27%     far upstream element (FUSE) binding protein 3
  FMR1       27%     fragile × mental retardation 1
  FKBP1A     27%     FK506 binding protein 1A, 12 kDa
  FDFT1      27%     farnesyl-diphosphate farnesyltransferase 1
  FAM3C      27%     family with sequence similarity 3, member C
  EWSR1      27%     Ewing sarcoma breakpoint region 1
  EPS8       27%     epidermal growth factor receptor pathway substrate 8
  EIF3S9     27%     eukaryotic translation initiation factor 3, subunit 9 eta, 116 kDa
  EFNA1      27%     ephrin-A1
  DYRK1A     27%     dual-specificity tyrosine-(Y)-phosphorylation regulated kinase 1A
  DLG1       27%     DLG1
  DDOST      27%     dolichyl-diphosphooligosaccharide-protein glycosyltransferase
  DCTN6      27%     dynactin 6
  DBI        27%     diazepam binding inhibitor (GABA receptor modulator, acyl-Coenzyme A binding)
  DAZAP2     27%     DAZ associated protein 2
  DAG1       27%     dystroglycan 1 (dystrophin-associated glycoprotein 1)
  CUL4A      27%     cullin 4A
  CSPG6      27%     chondroitin sulfate proteoglycan 6 (bamacan)
  COG2       27%     component of oligomeric golgi complex 2
  CEBPD      27%     CCAAT/enhancer binding protein (C/EBP), delta
  CDC34      27%     cell division cycle 34
  CD9        27%     CD9 antigen (p24)
  CCT6A      27%     chaperonin containing TCP1, subunit 6A (zeta 1)
  CBX3       27%     chromobox homolog 3 (HP1 gamma homolog, Drosophila)
  CARS       27%     cysteinyl-tRNA synthetase
  C1D        27%     nuclear DNA-binding protein
  C14orf32   27%     chromosome 14 open reading frame 32
  BUB3       27%     BUB3 budding uninhibited by benzimidazoles 3 homolog (yeast)
  BSG        27%     basigin (OK blood group)
  BLOC1S1    27%     biogenesis of lysosome-related organelles complex-1, subunit 1
  BIRC2      27%     baculoviral IAP repeat-containing 2
  ARMC2      27%     armadillo repeat containing 2
  ANP32A     27%     acidic (leucine-rich) nuclear phosphoprotein 32 family, member A

Oncomine meta-analysis of SUMO1 co-expressed genes at a cutoff of 27% overlap (4 studies).

A similar meta-analysis was attempted for SUMO2 and SUMO3. However, SUMO2 was not expressed to levels that allowed for meta-analysis, and the results of SUMO3 meta-analysis gave fewer co-expressed genes than for SUMO1 (Additional File [2](#S2){ref-type="supplementary-material"}). There was a small overlap (37 genes) of co-expressed genes of SUMO1:SUMO3, but this does not necessarily imply that both are involved in completely distinct pathways. Rather, the meta-analysis technique has a high false-negative rate meaning that while the co-expressed genes we see are significant we will never get full coverage of every co-expressed gene as the stringency level of analysis is high.

SUMO1 was also seen to be involved in cell death pathways. In 67% (10 out of 15) of the studies analyzed SUMO1 was co-expressed with the [d]{.ul}efender [a]{.ul}gainst cell [d]{.ul}eath (*DAD1*) gene. This was the highest co-expression with SUMO1 in the meta-analysis. As the name suggests DAD1 is anti-apoptotic and can be upregulated in cancer \[[@B13],[@B14]\]. Other SUMO1 co-expressed genes involved in cell death pathways include *RELA*, *FADD*, *BCL2A1*, *BAK1*, *TNFRSF1A*. The high co-expression with *DAD1*is a novel finding and may prove important to SUMO1 pathways.

*DEK*oncogene was the next highest co-expressed gene (53%) with SUMO1. The DEK protein is important for chromatin structure, and may also play a role in cell death pathways by inhibiting apoptosis \[[@B15]-[@B17]\].

While co-expression meta-analysis data has previously been shown to have a high correlation with known pathways in other studies \[[@B2],[@B3]\], prudence should still be used when interpreting novel findings until they can be proven in a separate experimental system. For this reason the meta-analysis list is presented here only as a predictive data-driven hypothesis. The next step is experimental analysis of DEK and DAD1 proteins to assess whether they are targets of SUMO1 conjugation, protein-complex partners of SUMO1, or act upstream or downstream of SUMO1.

In summary, it is interesting that both of the highest co-expressed genes of SUMO1 are anti-apoptotic, and it is tempting to speculate that this may be an important pathway of SUMO1 regulation.

Conclusion
==========

Using co-expression meta-analysis from the Oncomine database SUMO1 co-expressed with many gene products, some which are already known to be in SUMO1 pathways. Novel predicted pathway partners include the DEK oncogene and DAD1, both of which co-expressed in over half of all studies analyzed. However, in what regard they take part in SUMO1 pathways remains to be further investigated.
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